.Detalles del empleoTipo de empleo: Contrato indefinidoUbicación: Barcelona, Barcelona provinciaDescripción completa del empleoGrade: L2Location: BarcelonaJob type: Permanent, Full-timeAbout the jobAt Sanofi, we are driven by one purpose – we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We never settle and now we are creating a new paradigm with a first-in-class therapy in the Transplant therapeutic area.The transplant area has as its priority the development of a portfolio composed of several already authorized drugs in solid organ transplantation (SOT) to be complemented by the incorporation of a first-in-class treatment for chronic Graft versus Host disease (cGVHD), Belumosudil, in the near future and other under investigation potential indications. cGVHD is a serious condition which may occur after an allogenic Hematopoietic Stem Cell transplant (HSCT) with a high impact in patient's quality of life.We are a team passionate about science and how we can improve the lives of patients. We leverage our innovation and transformation to support patients. Cross-work is one of our hallmarks and each of us lives the Play to win behaviors. We embrace a diverse and inclusive culture that engages and develops people to deliver outstanding results.This is a chance to bring your energy, expertise, and experience to truly transformative and career-defining leadership roles where you can help change countless lives. In return, you will have a rare opportunity in pharma – the chance to help disrupt and delay a debilitating and widespread disease.Your core responsibilities will include:Being the trusted scientific partner to key external experts (incl. KOLs, haematologists, pneumologist, nephrologist and other scientific stakeholders), establishing and maintaining robust, long-term peer relationships.Conducting high-touch scientific exchange with experts from key accounts (e.G., KOLs in Centers of Excellence) and beyond (e.G., broader HCP groups/scientific stakeholders outside of Centers of Excellence) to convey a compelling and highly scientific narrative on Chronic Graft versus Host disease disease stages and SOT.Engaging with experts from key accounts (e.G., KOLs haematologists, pneumologist, nephrologist and other scientific stakeholders in Centers of Excellence) to share scientific data, answer scientific questions and support them in developing best practices.Linking internal partners to external thought leaders for education and research collaboration.Disseminating scientific information including innovative medical education materials and research concepts to KOLs and fostering medical and scientific information exchange between the medical community.Tailoring engagement to the different segments of stakeholders, based on comprehensive stakeholders' mapping (incl